CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation.
Acute Disease
Adolescent
Allografts
CD4 Lymphocyte Count
CD4-Positive T-Lymphocytes
/ immunology
Child
Child, Preschool
Female
Follow-Up Studies
Graft vs Host Disease
/ immunology
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Immune Reconstitution
Infant
Kaplan-Meier Estimate
Male
Proportional Hazards Models
Retrospective Studies
Severity of Illness Index
Treatment Outcome
Young Adult
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
11 02 2021
11 02 2021
Historique:
received:
29
06
2020
accepted:
04
10
2020
pubmed:
6
11
2020
medline:
2
7
2021
entrez:
5
11
2020
Statut:
ppublish
Résumé
Acute graft-versus-host-Disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). We previously showed that early CD4+ T-cell immune reconstitution (IR; CD4+ IR) predicts survival after HCT. Here, we studied the relation between CD4+ IR and survival in patients developing aGVHD. Pediatric patients undergoing first allogeneic HCT at University Medical Center Utrecht (UMC)/Princess Máxima Center (PMC) or Memorial Sloan Kettering Cancer Center (MSK) were included. Primary outcomes were nonrelapse mortality (NRM) and overall survival (OS), stratified for aGVHD and CD4+ IR, defined as ≥50 CD4+ T cells per μL within 100 days after HCT or before aGVHD onset. Multivariate and time-to-event Cox proportional hazards models were applied, and 591 patients (UMC/PMC, n = 276; MSK, n = 315) were included. NRM in patients with grade 3 to 4 aGVHD with or without CD4+ IR within 100 days after HCT was 30% vs 80% (P = .02) at UMC/PMC and 5% vs 67% (P = .02) at MSK. This was associated with lower OS without CD4+ IR (UMC/PMC, 61% vs 20%; P = .04; MSK, 75% vs 33%; P = .12). Inadequate CD4+ IR before aGVHD onset was associated with significantly higher NRM (74% vs 12%; P < .001) and inferior OS (24% vs 78%; P < .001). In this retrospective analysis, we demonstrate that early CD4+ IR, a simple and robust marker predictive of outcomes after HCT, is associated with survival after moderate to severe aGVHD. This association must be confirmed prospectively but suggests strategies to improve T-cell recovery after HCT may influence survival in patients developing aGVHD.
Identifiants
pubmed: 33150379
pii: S0006-4971(21)00281-0
doi: 10.1182/blood.2020007905
pmc: PMC7986048
doi:
Types de publication
Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
848-855Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2021 by The American Society of Hematology.
Références
Stem Cell Investig. 2017 May 16;4:38
pubmed: 28607912
Bone Marrow Transplant. 2015 Sep;50(9):1227-34
pubmed: 26052909
N Engl J Med. 2016 Jan 7;374(1):43-53
pubmed: 26735993
J Allergy Clin Immunol. 2017 Dec;140(6):1643-1650.e9
pubmed: 28392330
Clin Pharmacokinet. 2015 Apr;54(4):435-46
pubmed: 25466602
Sci Transl Med. 2013 Apr 3;5(179):179ra43
pubmed: 23552371
Transplantation. 1974 Oct;18(4):295-304
pubmed: 4153799
Biol Blood Marrow Transplant. 2015 Nov;21(11):1955-62
pubmed: 26187864
N Engl J Med. 2011 Dec 1;365(22):2055-66
pubmed: 22129252
Biol Blood Marrow Transplant. 2013 Feb;19(2):305-13
pubmed: 23092812
Clin Pharmacokinet. 2019 May;58(5):627-637
pubmed: 30327943
Biol Blood Marrow Transplant. 2015 Mar;21(3):473-82
pubmed: 25485863
Biol Blood Marrow Transplant. 2010 Jul;16(7):915-26
pubmed: 20226870
Blood. 2011 Jan 20;117(3):1061-70
pubmed: 20952687
Blood. 2012 Jan 5;119(1):296-307
pubmed: 22010102
Bone Marrow Transplant. 2008 Oct;42 Suppl 2:S54-9
pubmed: 18978746
Bone Marrow Transplant. 2014 Feb;49(2):168-73
pubmed: 23892326
Biol Blood Marrow Transplant. 2017 Apr;23(4):625-634
pubmed: 28104514
Bone Marrow Transplant. 2016 Oct;51(10):1376-1378
pubmed: 27159172
Acta Neurol Scand. 2009 Apr;119(4):239-45
pubmed: 18771523
Nat Med. 2003 Sep;9(9):1144-50
pubmed: 12925844
Biol Blood Marrow Transplant. 2010 Jul;16(7):907-14
pubmed: 20302964
Leuk Res. 2017 Jun;57:60-64
pubmed: 28292719
Haematologica. 2019 Jul;104(7):1309-1321
pubmed: 31221786
Am J Med. 1980 Aug;69(2):204-17
pubmed: 6996481
Biol Blood Marrow Transplant. 2009 Jul;15(7):881-5
pubmed: 19539221
Blood. 2016 Dec 8;128(23):2734-2741
pubmed: 27702800
J Allergy Clin Immunol. 2016 Jan;137(1):306-309.e4
pubmed: 26194539
Lancet Haematol. 2017 Apr;4(4):e183-e191
pubmed: 28330607
Lancet Haematol. 2015 May;2(5):e194-203
pubmed: 26688094
Bone Marrow Transplant. 1989 Jan;4(1):107-12
pubmed: 2647173
Bone Marrow Transplant. 2016 May;51(5):668-74
pubmed: 26808573
Blood. 2017 Aug 3;130(5):677-685
pubmed: 28588018
Biol Blood Marrow Transplant. 2016 May;22(5):902-9
pubmed: 26860636
Blood. 2018 Jun 21;131(25):2846-2855
pubmed: 29545329
Biol Blood Marrow Transplant. 2015 Oct;21(10):1839-45
pubmed: 26119367
Cytotherapy. 2020 Sep;22(9):503-510
pubmed: 32622752
Clin Cancer Res. 2014 Apr 15;20(8):2215-25
pubmed: 24573552
JCI Insight. 2017 Feb 9;2(3):e89798
pubmed: 28194439
Blood. 2006 Aug 15;108(4):1291-7
pubmed: 16627754